388 related articles for article (PubMed ID: 33467570)
1. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.
Bebb DG; Banerji S; Blais N; Desmeules P; Gill S; Grin A; Feilotter H; Hansen AR; Hyrcza M; Krzyzanowska M; Melosky B; Noujaim J; Purgina B; Ruether D; Simmons CE; Soulieres D; Torlakovic EE; Tsao MS
Curr Oncol; 2021 Jan; 28(1):523-548. PubMed ID: 33467570
[TBL] [Abstract][Full Text] [Related]
2. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients.
Perreault S; Chami R; Deyell RJ; El Demellawy D; Ellezam B; Jabado N; Morgenstern DA; Narendran A; Sorensen PHB; Wasserman JD; Yip S
Curr Oncol; 2021 Jan; 28(1):346-366. PubMed ID: 33435412
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients.
Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
[TBL] [Abstract][Full Text] [Related]
4. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
5. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
6. The promise of TRK inhibitors in pediatric cancers with NTRK fusions.
Blauel ER; Laetsch TW
Cancer Genet; 2022 Apr; 262-263():71-79. PubMed ID: 35108663
[TBL] [Abstract][Full Text] [Related]
7. Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force.
Lim KHT; Kong HL; Chang KTE; Tan DSW; Tan IBH; Mohamad F; Soh SY; Pang BN; Soo RA; Choo SP; Hsieh WS; Aung L
Asia Pac J Clin Oncol; 2022 Aug; 18(4):394-403. PubMed ID: 34806337
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis and therapy of tumors with NTRK gene fusion].
Stenzinger A; van Tilburg CM; Tabatabai G; Länger F; Graf N; Griesinger F; Heukamp LC; Hummel M; Klingebiel T; Hettmer S; Vokuhl C; Merkelbach-Bruse S; Overkamp F; Reichardt P; Scheer M; Weichert W; Westphalen CB; Bokemeyer C; Ivanyi P; Loges S; Schirmacher P; Wörmann B; Bielack S; Seufferlein TTW
Pathologe; 2021 Feb; 42(1):103-115. PubMed ID: 33258061
[TBL] [Abstract][Full Text] [Related]
9. NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy.
Haratake N; Seto T
Clin Lung Cancer; 2021 Jan; 22(1):1-5. PubMed ID: 33272813
[TBL] [Abstract][Full Text] [Related]
10. NTRK fusions in lung cancer: From biology to therapy.
Harada G; Santini FC; Wilhelm C; Drilon A
Lung Cancer; 2021 Nov; 161():108-113. PubMed ID: 34563714
[TBL] [Abstract][Full Text] [Related]
11. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
[TBL] [Abstract][Full Text] [Related]
12. NTRK fusions in solid tumours: what every pathologist needs to know.
Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA
Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338
[TBL] [Abstract][Full Text] [Related]
13. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
[TBL] [Abstract][Full Text] [Related]
14. Canadian consensus on TRK-inhibitor therapy for NTRK fusion-positive sarcoma.
Simmons C; Deyell RJ; MacNeill AJ; Vera-Badillo FE; Smrke A; Abdul Razak AR; Banerji S; McLeod D; Noujaim J
Int J Cancer; 2021 Nov; 149(9):1691-1704. PubMed ID: 34213775
[TBL] [Abstract][Full Text] [Related]
15. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
Kummar S; Shen L; Hong DS; McDermott R; Keedy VL; Casanova M; Demetri GD; Dowlati A; Melcón SG; Lassen UN; Leyvraz S; Liu T; Moreno V; Patel J; Patil T; Mallick AB; Sousa N; Tahara M; Ziegler DS; Norenberg R; Arvis P; Brega N; Drilon A; Tan DSW
Cancer; 2023 Dec; 129(23):3772-3782. PubMed ID: 37769113
[TBL] [Abstract][Full Text] [Related]
16. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
17. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China.
Xu C; Si L; Wang W; Li Z; Song Z; Wang Q; Liu A; Yu J; Fang W; Zhong W; Wang Z; Zhang Y; Liu J; Zhang S; Cai X; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Pu X; Lin R; Liu W; Rao C; Lv D; Yu Z; Lei L; Li X; Tang C; Zhou C; Zhang J; Xue J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Hu X; Zhou J; Zhu Z; Li Y; Qiu H; Xia F; Lu Y; Chen X; Ge R; Dai E; Han Y; Pan W; Luo J; Jia H; Dong X; Pang F; Wang K; Wang L; Zhu Y; Xie Y; Lin X; Cai J; Wei J; Lan F; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Wan B; Lv D; Wei Q; Kang J; Zhang J; Zhang C; Yu G; Ou J; Shi L; Li Z; Liu Z; Liu J; Yang N; Wu L; Wang H; Jin G; Yang L; Wang G; Fang M; Fang Y; Li Y; Wang X; Zhang Y; Ma S; Wang B; Zhang X; Song Y; Lu Y
Thorac Cancer; 2022 Nov; 13(21):3084-3097. PubMed ID: 36127731
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
Demetri GD; Antonescu CR; Bjerkehagen B; Bovée JVMG; Boye K; Chacón M; Dei Tos AP; Desai J; Fletcher JA; Gelderblom H; George S; Gronchi A; Haas RL; Hindi N; Hohenberger P; Joensuu H; Jones RL; Judson I; Kang YK; Kawai A; Lazar AJ; Le Cesne A; Maestro R; Maki RG; Martín J; Patel S; Penault-Llorca F; Premanand Raut C; Rutkowski P; Safwat A; Sbaraglia M; Schaefer IM; Shen L; Serrano C; Schöffski P; Stacchiotti S; Sundby Hall K; Tap WD; Thomas DM; Trent J; Valverde C; van der Graaf WTA; von Mehren M; Wagner A; Wardelmann E; Naito Y; Zalcberg J; Blay JY
Ann Oncol; 2020 Nov; 31(11):1506-1517. PubMed ID: 32891793
[TBL] [Abstract][Full Text] [Related]
19. How selecting best therapy for metastatic
Ekman S
Transl Lung Cancer Res; 2020 Dec; 9(6):2535-2544. PubMed ID: 33489816
[TBL] [Abstract][Full Text] [Related]
20. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
